- Home
- HROW vs TRIN Comparison
HROW vs TRIN Comparison
Compare HROW & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- TRIN
- Stock Information
- Founded
- HROW 1998
- TRIN 2007
- Country
- HROW United States
- TRIN United States
- Employees
- HROW N/A
- TRIN N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- TRIN Finance/Investors Services
- Sector
- HROW Health Care
- TRIN Finance
- Exchange
- HROW Nasdaq
- TRIN Nasdaq
- Market Cap
- HROW 1.1B
- TRIN 974.3M
- IPO Year
- HROW N/A
- TRIN 2021
- Fundamental
- Price
- HROW $33.02
- TRIN $15.33
- Analyst Decision
- HROW Strong Buy
- TRIN Hold
- Analyst Count
- HROW 7
- TRIN 3
- Target Price
- HROW $61.83
- TRIN $15.17
- AVG Volume (30 Days)
- HROW 453.8K
- TRIN 760.9K
- Earning Date
- HROW 08-11-2025
- TRIN 08-06-2025
- Dividend Yield
- HROW N/A
- TRIN 13.33%
- EPS Growth
- HROW N/A
- TRIN 37.07
- EPS
- HROW N/A
- TRIN 2.27
- Revenue
- HROW $212,858,000.00
- TRIN $254,887,000.00
- Revenue This Year
- HROW $46.17
- TRIN $24.11
- Revenue Next Year
- HROW $39.97
- TRIN $4.87
- P/E Ratio
- HROW N/A
- TRIN $6.74
- Revenue Growth
- HROW 53.49
- TRIN 33.44
- 52 Week Low
- HROW $20.85
- TRIN $12.50
- 52 Week High
- HROW $59.23
- TRIN $16.82
- Technical
- Relative Strength Index (RSI)
- HROW 48.64
- TRIN 67.77
- Support Level
- HROW $30.12
- TRIN $14.72
- Resistance Level
- HROW $33.90
- TRIN $15.19
- Average True Range (ATR)
- HROW 1.70
- TRIN 0.24
- MACD
- HROW -0.50
- TRIN 0.02
- Stochastic Oscillator
- HROW 36.39
- TRIN 69.42
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.